Ptprs and proteoglycans in autoimmune disease

A method of treating an autoimmune disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a PTPRS de-clustering agent, wherein administration treats the autoimmune disease in the subject, and wherein the de-clustering agent is not chondroitin sulfate.

A method of decreasing fibroblast activity in a subject, the method comprising administering to the subject a therapeutically effective amount of a PTPRS de-clustering agent, wherein administration decreases fibroblast activity in the subject, and wherein the de-clustering agent is not chondroitin sulfate.

A method of treating a fibroblast mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a PTPRS de-clustering agent, wherein administration treats the fibroblast-mediated disease in the subject, and wherein the de-clustering agent is not chondroitin sulfate.

A method of identifying a candidate PTPRS de-clustering agent, the method comprising contacting a test agent with clustered PTPRS peptides and detecting de-clustering of the PTPRS peptides, thereby identifying a candidate PTPRS de-clustering agent.

A method of identifying a candidate PTPRS de-clustering agent, the method comprises contacting a test agent with PTPRS and heparan sulfate and determining whether the test agent inhibits binding of the PTPRS to heparan sulfate, inhibition of binding indicating the test agent is a PTPRS de-clustering agent.